Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference Jul 31, 2018 4:45pm EDT
Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline Jun 25, 2018 8:00am EDT
Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas Jun 15, 2018 2:30am EDT
Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS) Jun 13, 2018 8:00am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 07, 2018 5:20pm EDT
Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer Jun 07, 2018 8:00am EDT
Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association May 17, 2018 9:00am EDT
Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress May 08, 2018 7:05am EDT
Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Autoimmune and Other Diseases May 08, 2018 7:00am EDT
